Publication Name	World Journal of Clinical Cases
Manuscript ID	83925
Country	China

Received	2023-03-01 06:33
Peer-Review Started	2023-03-01 06:37
First Decision by Editorial Office Director	2023-05-25 01:37
Return for Revision	2023-05-25 01:37
Revised	2023-06-21 07:03
Publication Fee Transferred
Second Decision by Editor	2023-07-11 02:55
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2023-07-11 08:14
Articles in Press	2023-07-11 08:14
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-07-27 11:22
Publish the Manuscript Online	2023-08-03 10:22

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Immunology
Manuscript Type	Case Report
Article Title	Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
Manuscript Source	Unsolicited Manuscript
All Author List	Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He and Qi Deng
ORCID	Author(s) ORCID Number Xiao-Dong Peng http://orcid.org/0000-0002-8441-0490 Qi Deng http://orcid.org/0000-0002-1591-9162
Funding Agency and Grant Number
Corresponding Author	Xiao-Dong Peng, MD, Chief Physician, Department of Cancer, The First Affiliated Hospital of Nanchang University, No. 1519 Dongyue Avenue, Nanchang 330006, Jiangxi Province, China. pxddhbb@163.com
Key Words	Malignant peritoneal mesothelioma; Immune checkpoint inhibitors; Immunotherapy; Zimberelimab; Chemotherapy; Case report
Core Tip	Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage. Here, we present the first case of a patient with epithelioid subtype MPeM, who was treatment-naïve and benefited from initial programmed cell death 1 inhibitor plus standard chemotherapy with a prolonged progression-free survival and good tolerance. We would like to share our experience with immunochemotherapy, which will help clinicians make appropriate decisions in the future.
Publish Date	2023-08-03 10:22
Citation	Peng XD, You ZY, He LX, Deng Q. Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature. World J Clin Cases 2023; 5296-5302
URL	https://www.wjgnet.com/2307-8960/full/v11/i22/5296.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i22.5296

Full Article (PDF)	WJCC-11-5296-with-cover.pdf
Full Article (Word)	WJCC-11-5296.docx
CARE Checklist–2016	83925-CARE-Checklist–2016-revision.pdf
Manuscript File	83925_Auto_Edited-JLW.docx
Answering Reviewers	83925-Answering reviewers.pdf
Audio Core Tip	83925-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	83925-Conflict-of-interest statement.pdf
Copyright License Agreement	83925-Copyright license agreement.pdf
Signed Consent for Treatment Form(s) or Document(s)	83925-Informed consent statement.pdf
Non-Native Speakers of English Editing Certificate	83925-Language certificate.pdf
Peer-review Report	83925-Peer-review(s).pdf
Scientific Misconduct Check	83925-Bing-Fan JR-2.png
Scientific Editor Work List	83925-Scientific editor work list.pdf
CrossCheck Report	83925-CrossCheck report.pdf
CrossCheck Report	83925-CrossCheck.png